The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials

BackgroundImmune checkpoint inhibitors (ICIs) plus fluorouracil-based chemotherapy (Chemo) have been approved as an initial treatment strategy for metastatic or recurrent human epidermal growth factor receptor 2 (HER2)-negative gastric cancer (GC) or gastroesophageal junction cancer (GEJC). However,...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Wenji Pu, Shasha Li, Jinliang Zhang, Jijie Huang, Jishi Li, Yong Jiang, Zhiyuan Xu, Fan Yi, Yuling Lan, Qin Xiao, Wenqi Chen, Jing Jin
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2025-03-01
Ráidu:	Frontiers in Immunology
Fáttát:	advanced gastroesophageal cancer immune check points PD-1/PD-L1 inhibitors chemotherapy gastroesophageal adenocarcinoma gastric adenocarcinoma
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1566939/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!